drugset / Trial / NCT06730022

Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds

NCT06730022 ↗

Expanded access Available Merakris Therapeutics

Summary

The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject MTX-001 Unknown — Subcutaneous